JORVEZA Drug Insight and Market Forecast - 2032

This “JORVEZA Drug Insight and Market Forecast - 2032” report provides comprehensive insights about JORVEZA for Eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the JORVEZA for EoE in the 5MM, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the JORVEZA for EoE. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JORVEZA market forecast analysis for EoE in the 5MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.

Drug Summary

Budesonide is a non-halogenated glucocorticosteroid, which acts primarily anti-inflammatory via binding to the glucocorticoid receptor. In treating EoE with JORVEZA, budesonide inhibits the antigen-stimulated secretion of many pro-inflammatory signal molecules such as thymic stromal lymphopoietin, IL-13, and eotaxin-3 in the esophageal epithelium, which results in a significant reduction of the esophageal eosinophilic inflammatory infiltrate. The efficacy and safety of JORVEZA were evaluated for the induction of clinicopathological remission of EoE in adults in pivotal clinical studies EOS-1 and EOS-2. Additionally, the EMA granted ODD to budesonide for the treatment of EoE. The recommended daily dose is 2 mg budesonide as one 1 mg tablet in the morning and one in the evening. The usual duration of treatment is 6 weeks.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the JORVEZA description, mechanism of action, dosage and administration, research and development activities in eosinophilic esophagitis (EoE).
• Elaborated details on JORVEZA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JORVEZA research and development activities in EoE across the Europe.
• The report also covers the patents information with expiry timeline around JORVEZA.
• The report contains forecasted sales of JORVEZA for EoE till 2032.
• Comprehensive coverage of the late-stage emerging therapies for EoE.
• The report also features the SWOT analysis with analyst views for JORVEZA in EoE.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JORVEZA Analytical Perspective

In-depth JORVEZA Market Assessment

This report provides a detailed market assessment of JORVEZA for eosinophilic esophagitis (EoE) in the seven major markets, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

JORVEZA Clinical Assessment

The report provides the clinical trials information of JORVEZA for EoE covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for eosinophilic esophagitis (EoE) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JORVEZA dominance.
• Other emerging products for EoE are expected to give tough market competition to JORVEZA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JORVEZA in EoE.
• This in-depth analysis of the forecasted sales data of JORVEZA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JORVEZA in EoE.

Key Questions

• What is the product type, route of administration and mechanism of action of JORVEZA?
• What is the clinical trial status of the study related to JORVEZA in eosinophilic esophagitis (EoE) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JORVEZA development?
• What are the key designations that have been granted to JORVEZA for EoE?
• What is the forecasted market scenario of JORVEZA for EoE?
• What are the forecasted sales of JORVEZA in the seven major countries, including Europe (Germany, France, Italy, Spain) and the United Kingdom?
• What are the other emerging products available and how are these giving competition to JORVEZA for EoE?
• Which are the late-stage emerging therapies under development for the treatment of EoE?

This product will be delivered within 2 business days.